NATERA, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
NATERA, INC. (NTRA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $130.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-02-27
- NATERA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $28.18M, a 83.59% decline year-over-year.
- NATERA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $171.72M.
- NATERA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$62.94M, a 185.15% decline year-over-year.
- NATERA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was $73.91M, a 349.75% increase year-over-year.
- NATERA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $130.55M, a 56.98% decline from fiscal 2024.
- NATERA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $303.49M, a 72.43% increase from fiscal 2023.
- NATERA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $176.00M, a 53.86% decline from fiscal 2022.
- NATERA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $381.48M, a 966.80% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-12-31 | $130.55M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $95.85M 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $54.43M 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | $28.18M 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $303.49M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $250.75M 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | $154.70M 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | $171.72M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $176.00M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $202.62M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$84.98M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | -$62.94M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $381.48M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | -$27.49M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $6.77M 10-Q · filed 2023-08-04 | |||
| 2022-03-31 | $73.91M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $35.76M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $46.48M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $14.18M 10-Q · filed 2022-08-05 | |||
| 2021-03-31 | $16.43M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | -$13.13M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $147.55M 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | $15.40M 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | $12.22M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $10.98M 10-K · filed 2022-02-25 | |||
| 2019-09-30 | $660.00K 10-Q · filed 2020-11-06 | $660.00K 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | -$21.02M 10-Q · filed 2020-08-07 | -$21.02M 10-Q · filed 2019-08-09 | ||
| 2019-03-31 | -$16.32M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $37.98M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $26.08M 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | $5.24M 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | $26.67M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | -$3.67M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | -$5.09M 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | -$8.45M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | -$13.84M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |